Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Alimta

 
National Institutes of Health

Related topics

Related topics

6 relations
LY 231514pemetrexed 500 MG Injection [Alimta]pemetrexed Injection [Alimta]

Broader (3)

pemetrexedpemetrexed disodiumpemetrexed disodium heptahydrate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
On August 19, 2004, pemetrexed for injection (Alimta); Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com) received… Expand
Is this relevant?
Review
2004
Review
2004
Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic Agent
  • A. Adjei
  • Clinical Cancer Research
  • 2004
    • Corpus ID: 31467685
Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma
The underpinning conceptual model for the Lung Cancer Symptom Scale (LCSS), an instrument used to assess health‐related quality… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The Role of α-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs
Purpose: Raltitrexed, pemetrexed, lometrexol, and ZD9331 are antifolate drugs transported into cells via the ubiquitously… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.
BACKGROUND The purpose of this study was to evaluate ALIMTA (pemetrexed disodium, LY231514), a multi-targeted antifolate with… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
Pemetrexed (ALIMTA, MTA) is a novel thymidylate synthase (TS) inhibitor and has shown activity against colon cancer, mesothelioma… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
The purpose of this study was to identify predictive factors for severe toxicity caused by antifolate-chemotherapy using… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
BACKGROUND To evaluate the efficacy and safety of pemetrexed therapy for chemotherapy-naïve patients with surgically incurable… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.
BACKGROUND To evaluate the activity of MTA plus cisplatin in chemotherapy-naive patients with non-small cell lung cancer (NSCLC… Expand
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
PURPOSE To determine the safety and activity of LY231514 (ALIMTA, MTA, pemetrexed disodium, Eli Lilly and Co., Indianapolis, IN… Expand
  • table 1
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE